

16 November 2017

Phase 1 Clinical Trial Results Published in International Medical Journal

MMJ PhytoTech Limited (ASX: MMJ) (“MMJ” or “the Company”) is pleased to advise that results from the Phase 1 Clinical Trial undertaken by MMJ’s wholly-owned, Israeli-based subsidiary PhytoTech Therapeutics Ltd (“PTL”) have been published. The article “Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology” has been published in *Clinical Pharmacology in Drug Development* (“CPDD”).

Established in 2012, CPDD is an international, peer-reviewed publication and the official journal of the American College of Clinical Pharmacology, providing a forum for the presentation of first-time-in-man study results. CPDD publishes high-quality clinical pharmacology studies in drug development which are primarily (but not exclusively) performed in early development phases in healthy subjects.

PTL completed its Phase 1 Clinical Trial of the PTL101 capsules in March 2016, with results demonstrating the safety and high performance of the oral capsule technology, including the effective delivery profile of cannabidiol (“CBD”) compound to trial subjects.

The Phase 1 Clinical Trial also highlighted the favourable bioavailability of the capsules in comparison to Sativex – a market-leading, commercially available cannabinoid oral spray produced by GW Pharmaceuticals (LON: GWP) (NASDAQ: GWPH).

The PTL101 drug beads utilise a proprietary formulation developed through the Company’s Gelpell-CBD™ product technology, which contain organically derived, highly purified CBD.

Phase 2 Clinical Trial Update

PTL has since commenced its Phase 2 Clinical Trial into the efficacy of the PTL101 capsules in treating refractory epilepsy in children.

The completion of this Phase 2 Clinical Trial would be a major catalyst towards the commercial development of the PTL101 capsules, with MMJ potentially only the third company behind GW Pharmaceuticals and Insys Therapeutics Inc. (NASDAQ: INSY) to present results of a formal Phase 2 Clinical Trial into refractory epilepsy in children.

In addition, a Phase 2 Clinical Trial into the safety and efficacy of the Company’s PTL201 capsules in treating spasticity related symptoms of multiple sclerosis (“MS”) patients is planned to commence in due course.

– ENDS –

ASX RELEASE

For media and investor inquiries please contact:

Andreas Gedeon
Managing Director
+1 (250) 713 6302
agedeon@mmj.ca

Released through Sam Burns, Six Degrees Investor Relations, M: +61 400 164 067



Follow us on Twitter @MMJPhytoTechLtd

<http://www.mmjphytotech.com.au>

About MMJ PhytoTech Limited

MMJ PhytoTech Limited (ASX. MMJ) is focused on becoming a large-scale cannabis producer, targeting direct supply to the growing Canadian medical and recreational markets which will have an estimated combined value of C\$8-9 billion by 2024. The Company controls operations across the entire medicinal cannabis value chain through its ~59% interest in TSX-V listed **Harvest One Cannabis Inc** (TSXV: HVST) and its 100% interest in Israeli research and development subsidiary, **PhytoTech Therapeutics Ltd**, both of which are strategically located in favourable jurisdictions with supportive regulatory frameworks in place.